Short Bowel Syndrome Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals

DelveInsight's "Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the Short Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Short Bowel Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Short Bowel Syndrome Market Forecast
https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Short Bowel Syndrome Market Report:
• The Short Bowel Syndrome market size across the 7MM is forecast to expand from USD 2,450 million in 2025 to USD 3,994 million by 2034, reflecting a projected CAGR of 5.6% across major markets including the US, EU4, the UK, and Japan.
• In July 2025, OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) announced that their abstract, titled "First-in-Class Oral GLP-2 Analog for the Treatment of Short Bowel Syndrome," has been chosen for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress. The event will be held from September 13 to 16, 2025, in Prague, Czech Republic.
• In June 2025, Zealand Pharma A/S (Nasdaq: ZEAL), a biotech company specializing in advanced peptide-based therapies, has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for glepaglutide. This extended-release GLP-2 analog is intended for use in adult patients suffering from short bowel syndrome (SBS).
• In April 2025, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotech firm focused on developing breakthrough treatments for gastrointestinal and rare diseases, announced that, following recent interactions with the U.S. FDA, a Phase 3 trial will be required to support the approval of apraglutide for patients with short bowel syndrome (SBS) and intestinal failure (IF) who rely on parenteral support. As the company continues advancing apraglutide's development, it has partnered with Goldman Sachs & Co. LLC to assess strategic options aimed at maximizing value for shareholders.
• In March 2025, Ironwood Pharmaceuticals (Nasdaq: IRWD) was a biotechnology company dedicated to developing and commercializing transformative therapies for individuals with gastrointestinal (GI) and rare diseases. The company is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog designed for short bowel syndrome patients reliant on parenteral support. Additionally, Ironwood has been instrumental in developing LINZESS® (linaclotide), the leading U.S. prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
• In December 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for glepaglutide. The long-acting GLP-2 analog is being developed to treat adult patients with short bowel syndrome (SBS) and intestinal failure (IF) who rely on parenteral support.
• In February 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has unveiled promising top-line outcomes from its pivotal Phase III STARS trial. This trial assessed the effectiveness and safety of subcutaneous apraglutide administered once weekly in reducing the dependency on parenteral support (PS) in adult patients diagnosed with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF is a rare and severe condition resulting in organ failure, where patients rely on PS. Approximately 18,000 adult patients in the United States, Europe, and Japan are affected by this condition. Following these findings, Ironwood intends to submit a new drug application (NDA) and other regulatory documents for apraglutide aimed at treating adult SBS patients reliant on PS.
• The US Short Bowel Syndrome treatment market was valued at approximately USD 2,100 million in 2024 and is projected to grow with the introduction of new therapies and the label expansions of existing treatments.
• GATTEX received FDA and EMA approval in 2012 for adult SBS patients requiring parenteral nutrition and was later approved for pediatric use. With upcoming patent expirations and the anticipated introduction of generics in Europe, a decline in revenue is expected.
• Companies are actively pursuing the development of therapies for short bowel syndrome, with candidates such as glepaglutide, apraglutide, and HM15912 currently under evaluation for potential future market approval.
• In 2024, the United States had the highest number of prevalent short bowel syndrome (SBS) cases among the 7MM, with around 14,000 cases, followed by the EU4 and the UK. Surgical complications remain a major factor driving SBS prevalence in the country.
• Short bowel syndrome is more prevalent in females than males. In the United States, over 67% of SBS patients were women. Anatomical differences play a significant role, as women generally have a shorter baseline small intestine length than men, making them more susceptible to developing SBS following extensive bowel resections.
• In the United States in 2024, approximately 29% of short bowel syndrome (SBS) cases were attributed to surgical complications, while around 24% resulted from mesenteric infarction. Overall, SBS mainly develops due to surgical complications, mesenteric ischemia, Crohn's disease, neoplasms, and radiation enteritis, with surgical complications and ileus accounting for the largest proportion of cases.
• Within the EU4 and the UK, Germany recorded the largest number of prevalent short bowel syndrome cases in 2024, whereas Spain had the lowest prevalence.
• Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others
• Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
• The Short Bowel Syndrome epidemiology based on gender analyzed that Short Bowel Syndrome affects females more than males
• The Short Bowel Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Short Bowel Syndrome pipeline products will significantly revolutionize the Short Bowel Syndrome market dynamics.

Short Bowel Syndrome Overview
Short Bowel Syndrome (SBS), also known as short gut syndrome, is a complex disorder that occurs when a significant portion of the small intestine is missing or nonfunctional. The small intestine is responsible for absorbing nutrients from the food we eat into the bloodstream. When a substantial portion of it is surgically removed due to conditions like Crohn's disease, ischemic bowel disease, or traumatic injury, it can result in SBS.

Get a Free sample for the Short Bowel Syndrome Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Short Bowel Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Short Bowel Syndrome Epidemiology Segmentation:
The Short Bowel Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Short Bowel Syndrome
• Prevalent Cases of Short Bowel Syndrome by severity
• Gender-specific Prevalence of Short Bowel Syndrome
• Diagnosed Cases of Episodic and Chronic Short Bowel Syndrome

Download the report to understand which factors are driving Short Bowel Syndrome epidemiology trends @ Short Bowel Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Short Bowel Syndrome market or expected to get launched during the study period. The analysis covers Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Short Bowel Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Short Bowel Syndrome Therapies and Key Companies
• Glepaglutide: Zealand Pharma
• Apraglutide: Ironwood Pharmaceuticals
• HM15912: Hanmi Pharmaceutical
• Teduglutide: Shire
• Pancreatic Enzyme: AbbVie
• HM15912 Active: Hanmi Pharma
• Somatropin: EMD Serono
• ZP1848: Zealand Pharma
• FE203799: VectivBio AG
• Clinolipid: Baxter Healthcare

Discover more about therapies set to grab major Short Bowel Syndrome market share @ Short Bowel Syndrome Treatment Landscape
https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Short Bowel Syndrome Market Strengths
• In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.
• Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Short Bowel Syndrome Market Opportunities
• Several organizations are actively working to provide information and increase awareness of such disorders.
• There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

Scope of the Short Bowel Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others
• Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
• Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies
• Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Short Bowel Syndrome Unmet Needs, KOL's views, Analyst's views, Short Bowel Syndrome Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.